PT1044203E - Derivados epimericos 3' do k-252a - Google Patents
Derivados epimericos 3' do k-252aInfo
- Publication number
- PT1044203E PT1044203E PT98964309T PT98964309T PT1044203E PT 1044203 E PT1044203 E PT 1044203E PT 98964309 T PT98964309 T PT 98964309T PT 98964309 T PT98964309 T PT 98964309T PT 1044203 E PT1044203 E PT 1044203E
- Authority
- PT
- Portugal
- Prior art keywords
- epimeric
- derivatives
- compounds
- epimeric derivatives
- survival
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002932 cholinergic neuron Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7026397P | 1997-12-31 | 1997-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1044203E true PT1044203E (pt) | 2003-07-31 |
Family
ID=22094212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98964309T PT1044203E (pt) | 1997-12-31 | 1998-12-30 | Derivados epimericos 3' do k-252a |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6093713A (enExample) |
| EP (1) | EP1044203B1 (enExample) |
| JP (1) | JP4405667B2 (enExample) |
| KR (1) | KR20010033737A (enExample) |
| CN (1) | CN1285836A (enExample) |
| AT (1) | ATE234308T1 (enExample) |
| AU (1) | AU1947499A (enExample) |
| BR (1) | BR9814543A (enExample) |
| CA (1) | CA2315953C (enExample) |
| DE (1) | DE69812177T2 (enExample) |
| DK (1) | DK1044203T3 (enExample) |
| ES (1) | ES2194385T3 (enExample) |
| NO (1) | NO20003397L (enExample) |
| PT (1) | PT1044203E (enExample) |
| WO (1) | WO1999033836A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2275373C2 (ru) * | 2000-12-08 | 2006-04-27 | Орто-Макнейл Фармасьютикал, Инк. | Макрогетероциклические соединения |
| US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| DE10161940A1 (de) * | 2001-12-17 | 2003-07-03 | Nad Ag | N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren |
| US6723844B1 (en) * | 2003-02-27 | 2004-04-20 | Abbott Laboratories | Preparation of K-252a |
| DE102004025726B4 (de) * | 2004-05-26 | 2006-07-06 | Roder, Hanno, Dr. | Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit |
| US20060058250A1 (en) * | 2004-09-10 | 2006-03-16 | Cephalon, Inc. | Methods of treating proliferative skin diseases using carbazole derivatives |
| US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
| EP2124554B1 (en) * | 2006-12-14 | 2012-02-08 | Tautatis, Inc. | Compositions and methods for the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質ｋ−２５２の誘導体 |
| JPH0826036B2 (ja) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質ｋ−２５２の誘導体 |
| WO1988007045A1 (fr) * | 1987-03-09 | 1988-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
| US5621100A (en) * | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| WO1994027982A1 (en) | 1993-05-28 | 1994-12-08 | Cephalon, Inc. | Use of indolocarbazole derivatives to treat a pathological condition of the prostate |
| US5468872A (en) * | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
| US5585488A (en) * | 1994-07-04 | 1996-12-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing indolocarbazole derivatives |
| WO1997005140A1 (en) | 1995-07-31 | 1997-02-13 | Novartis Ag | Trindene compounds |
| WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
-
1998
- 1998-12-30 CN CN98812812A patent/CN1285836A/zh active Pending
- 1998-12-30 KR KR1020007007260A patent/KR20010033737A/ko not_active Withdrawn
- 1998-12-30 CA CA2315953A patent/CA2315953C/en not_active Expired - Fee Related
- 1998-12-30 AU AU19474/99A patent/AU1947499A/en not_active Abandoned
- 1998-12-30 AT AT98964309T patent/ATE234308T1/de not_active IP Right Cessation
- 1998-12-30 WO PCT/US1998/027644 patent/WO1999033836A1/en not_active Ceased
- 1998-12-30 DE DE69812177T patent/DE69812177T2/de not_active Expired - Lifetime
- 1998-12-30 DK DK98964309T patent/DK1044203T3/da active
- 1998-12-30 EP EP98964309A patent/EP1044203B1/en not_active Expired - Lifetime
- 1998-12-30 JP JP2000526515A patent/JP4405667B2/ja not_active Expired - Fee Related
- 1998-12-30 US US09/223,518 patent/US6093713A/en not_active Expired - Lifetime
- 1998-12-30 BR BR9814543-6A patent/BR9814543A/pt not_active Application Discontinuation
- 1998-12-30 PT PT98964309T patent/PT1044203E/pt unknown
- 1998-12-30 ES ES98964309T patent/ES2194385T3/es not_active Expired - Lifetime
-
2000
- 2000-02-15 US US09/503,812 patent/US6451786B1/en not_active Expired - Fee Related
- 2000-06-29 NO NO20003397A patent/NO20003397L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20003397L (no) | 2000-08-31 |
| DE69812177T2 (de) | 2004-01-15 |
| AU1947499A (en) | 1999-07-19 |
| US6093713A (en) | 2000-07-25 |
| CA2315953C (en) | 2010-11-09 |
| WO1999033836A1 (en) | 1999-07-08 |
| JP2001527079A (ja) | 2001-12-25 |
| CN1285836A (zh) | 2001-02-28 |
| KR20010033737A (ko) | 2001-04-25 |
| ES2194385T3 (es) | 2003-11-16 |
| WO1999033836A9 (en) | 2000-09-14 |
| DK1044203T3 (da) | 2003-07-14 |
| NO20003397D0 (no) | 2000-06-29 |
| JP4405667B2 (ja) | 2010-01-27 |
| CA2315953A1 (en) | 1999-07-08 |
| ATE234308T1 (de) | 2003-03-15 |
| EP1044203B1 (en) | 2003-03-12 |
| EP1044203A1 (en) | 2000-10-18 |
| BR9814543A (pt) | 2000-10-10 |
| DE69812177D1 (de) | 2003-04-17 |
| US6451786B1 (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2175079T3 (es) | Derivados de indol utiles como inhibidores de cgmp-pde. | |
| CU23126A3 (es) | Inhibicion de kinasa raf usando ureas heterociclicas sustituidas | |
| NO962059L (no) | Antiarytmiske benzodiazepiner | |
| ZA981936B (en) | Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase. | |
| HN1998000143A (es) | Tetrahidronaftalenos substituidos y compuestos analogos. | |
| TR200000197T2 (tr) | Yeni bileşimler | |
| TR199902538T2 (xx) | Yeni bile�imler. | |
| TR200101567T2 (tr) | Yeni triazolo(4.5-D)pirimidin bileşimleri. | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| MX9603479A (es) | Derivados de 4-amino de acido micofenolico con actividad inmunosupresora. | |
| DK1017391T3 (da) | Tabletformulering med forlænget frigivelse til behandling af parkinsons sygdom | |
| CA2174494A1 (en) | Benzofurans | |
| DE69622871D1 (de) | Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat | |
| CA2270964A1 (en) | Benzonaphthyridines as bronchial therapeutics | |
| FI912621A7 (fi) | Farmakologisesti aktiivisia keskushermostoon vaikuttavia yhdisteitä | |
| NO985622L (no) | Utvalgte derivater av K-252A | |
| NO20003397L (no) | 3 '-epimerie K-252A-derivater | |
| FI944014A0 (fi) | Makrolidien desosaminojohdannaiset immuunivastetta heikentävinä aineina ja sieniä vastustavina aineina | |
| BR0115121A (pt) | Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas | |
| FI912622A7 (fi) | Farmakologisesti aktiivisia keskushermostoon vaikuttavia yhdisteitä | |
| DE69623819D1 (de) | Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten | |
| FI895069A0 (fi) | Funktionsanordning av modulkonstruktion foer valsarna i en maskinkalander. | |
| TR199900013T2 (xx) | Yeni bile�ikler. | |
| TR200003580T2 (tr) | Farnesil protein transferazı'nın önlenmesine mahsus benzo(5,6)siklohepta(1,2-B)piridin türevleri | |
| PT1104419E (pt) | Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao |